🔹 Revenue: $143.8M (Est. $144.6M) 🟡; UP +32% YoY
🔹 EPS: $0.66 (Est. $0.36) 🟢; UP +83% YoY
🔹 Gross Margin: 59% vs. 56% YoY
Outlook (FY25)
🔹 Revenue: $595M–$605M (Est. $600.4M) 🟢; midpoint +36% YoY
Operational Highlights
🔹 Net Income: $24.3M; 17% margin
🔹 Operating Expenses: $61.3M vs. $56.9M YoY
🔹 21 owned aircraft as of Q3; 22 as of Oct 29
🔹 Partnership with Mercedes-Benz to deploy dedicated organ transport fleet in Italy
🔹 OCS and NOP program expansion driving liver and heart volume growth
🔹 Cash: $466M
CEO Commentary – Waleed Hassanein, M.D.
🔸 “We’re focused on ending 2025 strong and building for another growth year in 2026.”
🔸 “Our OCS technology and NOP ecosystem uniquely position us for long-term leadership in global organ transplantation.”